Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Scynexis (SCYX) Shares Outstanding (Diluted Average) (2016 - 2026)

Scynexis filings provide 11 years of Shares Outstanding (Diluted Average) readings, the most recent being $51.0 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 3.08% to $51.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $51.0 million, a 3.08% increase, with the full-year FY2025 number at $49.9 million, up 2.93% from a year prior.
  • Shares Outstanding (Diluted Average) hit $51.0 million in Q1 2026 for Scynexis, up from $49.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $51.0 million in Q1 2026 to a low of $42.6 million in Q4 2022.
  • Median Shares Outstanding (Diluted Average) over the past 4 years was $49.4 million (2025), compared with a mean of $48.7 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): soared 61.51% in 2022 and later increased 2.22% in 2025.
  • Scynexis' Shares Outstanding (Diluted Average) stood at $42.6 million in 2022, then rose by 13.84% to $48.5 million in 2024, then increased by 2.93% to $49.9 million in 2025, then rose by 2.05% to $51.0 million in 2026.
  • The last three reported values for Shares Outstanding (Diluted Average) were $51.0 million (Q1 2026), $49.9 million (Q4 2025), and $49.7 million (Q3 2025) per Business Quant data.